ADAM20P2

Across TCGA pan-cancer cohorts, ADAM20P2 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated ADAM20P2 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ADAM20P2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM20P2 expression acts as an unfavorable survival marker, although some lineages such as PAAD show a favorable association.

BLCA, STAD, and LAML are the cancer types where ADAM20P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.195	0.713	<.001	144	view →
STAD	DFS	Tertile	All	0.470	0.726	.025	18	view →
LAML	DFS	Tertile	All	0.157	0.584	.005	18	view →
KIRC	DFS	Tertile	All	0.263	0.636	.013	18	view →
GBM	OS	Median	All	0.215	0.294	.042	8	view →
PAAD	DFS	Tertile	All	1.000	0.338	.048	6	view →
SKCM	OS	Tertile	All	0.682	0.875	.018	6	view →
UCEC	OS	Tertile	All	0.880	0.928	.040	6	view →
SARC	OS	Tertile	All	0.214	0.605	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ADAM20P2–BLCA (OS)

Open the BLCA breakdown →